Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SPARK Neuro has developed an FDA-cleared, non-invasive EEG-based diagnostic platform (“SPARK Scan”) that enables objective and scalable assessment of cognitive function. The company’s technology supports early detection of dementia and TBI at the point of care. Clinical collaborations with Mayo Clinic and Johns Hopkins Medicine have validated its utility in real-world settings. The company focuses on improving diagnosis rates for dementia—where up to 40% of cases are undiagnosed—and enabling earlier intervention.
No drug or therapeutic clinical trial results; focus is on device validation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SPARK Neuro.